Literature DB >> 11988484

CD36 mediates the cardiovascular action of growth hormone-releasing peptides in the heart.

V Bodart1, M Febbraio, A Demers, N McNicoll, P Pohankova, A Perreault, T Sejlitz, E Escher, R L Silverstein, D Lamontagne, H Ong.   

Abstract

Growth hormone-releasing peptides (GHRPs) are known as potent growth hormone secretagogues whose actions are mediated by the ghrelin receptor, a G protein-coupled receptor cloned from pituitary libraries. Hexarelin, a hexapeptide of the GHRP family, has reported cardiovascular activity. To identify the molecular target mediating this activity, rat cardiac membranes were labeled with a radioactive photoactivatable derivative of hexarelin and purified using lectin affinity chromatography and preparative gel electrophoresis. A binding protein of M(r) 84 000 was identified. The N-terminal sequence determination of the deglycosylated protein was identical to rat CD36, a multifunctional glycoprotein, which was expressed in cardiomyocytes and microvascular endothelial cells. Activation of CD36 in perfused hearts by hexarelin was shown to elicit an increase in coronary perfusion pressure in a dose-dependent manner. This effect was lacking in hearts from CD36-null mice and hearts from spontaneous hypertensive rats genetically deficient in CD36. The coronary vasoconstrictive response correlated with expression of CD36 as assessed by immunoblotting and covalent binding with hexarelin. These data suggest that CD36 may mediate the coronary vasospasm seen in hypercholesterolemia and atherosclerosis.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11988484     DOI: 10.1161/01.res.0000016164.02525.b4

Source DB:  PubMed          Journal:  Circ Res        ISSN: 0009-7330            Impact factor:   17.367


  33 in total

Review 1.  Regulation of platelet function by class B scavenger receptors in hyperlipidemia.

Authors:  Alejandro Zimman; Eugene A Podrez
Journal:  Arterioscler Thromb Vasc Biol       Date:  2010-11-11       Impact factor: 8.311

Review 2.  Ghrelin and GHS on cardiovascular applications/functions.

Authors:  J Isgaard; I Johansson
Journal:  J Endocrinol Invest       Date:  2005-10       Impact factor: 4.256

3.  OxLDL or TLR2-induced cytokine response is enhanced by oxLDL-independent novel domain on mouse CD36.

Authors:  Chenghui Xie; Hangpong Ng; Shanmugam Nagarajan
Journal:  Immunol Lett       Date:  2011-01-31       Impact factor: 3.685

Review 4.  CD36: implications in cardiovascular disease.

Authors:  Maria Febbraio; Roy L Silverstein
Journal:  Int J Biochem Cell Biol       Date:  2007-03-23       Impact factor: 5.085

Review 5.  The macrophage scavenger receptor at 30 years of age: current knowledge and future challenges.

Authors:  David R Greaves; Siamon Gordon
Journal:  J Lipid Res       Date:  2008-12-11       Impact factor: 5.922

Review 6.  Implications of ghrelin and hexarelin in diabetes and diabetes-associated heart diseases.

Authors:  Rasha Mofeed Habeeb Mosa; Zhen Zhang; Renfu Shao; Chao Deng; Jiezhong Chen; Chen Chen
Journal:  Endocrine       Date:  2015-02-04       Impact factor: 3.633

7.  Hexarelin: a multi-receptor peptide.

Authors:  R Deghenghi
Journal:  J Endocrinol Invest       Date:  2008-07       Impact factor: 4.256

8.  Increased CD36 expression in middle-aged mice contributes to obesity-related cardiac hypertrophy in the absence of cardiac dysfunction.

Authors:  Miranda M Y Sung; Debby P Y Koonen; Carrie-Lynn M Soltys; René L Jacobs; Maria Febbraio; Jason R B Dyck
Journal:  J Mol Med (Berl)       Date:  2011-03-10       Impact factor: 4.599

9.  Soluble CD36 ectodomain binds negatively charged diacylglycerol ligands and acts as a co-receptor for TLR2.

Authors:  Maximiliano J Jimenez-Dalmaroni; Nengming Xiao; Adam L Corper; Petra Verdino; Gary D Ainge; Dave S Larsen; Gavin F Painter; Pauline M Rudd; Raymond A Dwek; Kasper Hoebe; Bruce Beutler; Ian A Wilson
Journal:  PLoS One       Date:  2009-10-22       Impact factor: 3.240

10.  Integrating GHS into the Ghrelin System.

Authors:  Johannes D Veldhuis; Cyril Y Bowers
Journal:  Int J Pept       Date:  2010-03-18
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.